BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioLife Solutions reports record revenue and projects strong growth

BioLife Solutions delivered strong financial performance in Q4 2022, with record revenue and growth across key revenue platforms.
Despite challenges in operating expenses and gross margin, the company remains optimistic about future growth and profitability.
By focusing on high-margin revenues, supply chain enhancements, and allogeneic therapies, BioLife is strategically positioned for long-term success.

BioLife Solutions reports revenue growth and strategic business evaluation

BioLife Solutions reported solid Q1 2023 performance with revenue growth and improved gross margin, despite short-term EBITDA challenges.
The company is strategically evaluating underperforming businesses while focusing on high-margin recurring revenue streams for future growth.
CEO's balanced approach of maintaining strengths and exploring new projects signals a commitment to sustainable profitability and innovation.
BioLife's emphasis on efficiency and strategic planning positions it well for navigating market uncertainties and driving long-term success.

BioLife Solutions reports Q2 revenue decline, focuses on strategic growth

BioLife Solutions navigated challenges in Q2 2023 with a strategic focus on higher-margin streams and a strong pipeline for growth.
Despite a decrease in revenue and challenges in key markets, the company's divestiture plans and revenue guidance reflect confidence in future performance.
Analysts' concerns about capacity constraints and operational challenges highlight areas for improvement and strategic focus for BioLife Solutions.

BioLife Solutions faces revenue decline in Q3 but eyes market growth

BioLife Solutions navigated challenges in Q3 2023 with a decline in revenue and negative adjusted EBITDA, but remains optimistic about its market position and potential for revenue recovery. Strategic divestiture plans and a focus on core products aim to drive profitability and growth.

BioLife Solutions reports 11% revenue decrease in 2023

BioLife Solutions navigated revenue challenges in 2023, with a focus on higher margin revenue streams and operational efficiency.
Despite revenue declines, the company remains optimistic about future growth opportunities in the cell processing sector.
Proactive supply chain management and a diversified supplier base position BioLife well to mitigate risks and ensure operational continuity.
Strategic plans to divest underperforming product lines and optimize operations indicate a path towards improved financial performance.

BioLife Solutions excels in Q3, shifts focus to high-margin CGT tools

BioLife Solutions demonstrated robust performance in Q3 2024, driven by strong revenue growth and strategic divestment decisions.
The company's focus on becoming a pure-play CGT tools provider and emphasis on high-margin products signal a clear strategic direction.
While facing challenges in transitioning its business model, BioLife is well-equipped to capitalize on opportunities in the growing biopreservation market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash. , March 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided commentary on its current banking relationship with Silicon Valley Bank ("SVB").

BioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley Bank

BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2022 financial results will be released after market close on Thursday, March 16, 2023.

BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023

Exclusive global supplier of non-toxic, non-flammable PCM; first to operate at -70 ° C, meeting critical temperature requirement of biologic materials. BOTHELL, Wash.

BioLife Solutions Launches Ultraguard™ -70°C Phase Change Material (PCM) Accessory to Provide Backup Cooling in ULT Freezers and Dry Ice Alternative for Benchtop Biologic Material Storage

BOTHELL, Wash. , Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced the dates of its 2023 analyst day and upcoming investor conferences where management will be presenting and meeting with current and prospective investors.

BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences

Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of $161.9 million up 36% over 2021, with organic revenue growth of 38% and Cell Processing Platform revenue growth of 53% Initial revenue guidance for 2023 of $188 million to $202 million, reflecting overall growth of 16% to 25% over 2022, and excluding COVID related revenue, growth of 26% to 35% over 2022 BOTHELL, Wash. , Jan. 9, 2023 /PRNewswire/ --  BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2022 fourth quarter and full year preliminary unaudited revenue and introduced 2023 revenue guidance.

BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance

BioLife Solutions, Inc. guidance narrowed for full-year estimates, whilst there were several observable challenges exhibited in Q3 numbers. It could be a while before the company returns back to profitability, hence, the investment and valuation metrics don't stack up at present.

BioLife Solutions: Inventory Movement A Key Benchmarking Factor, Retain Hold

Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL, Wash.

BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023

7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash. , Nov. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today provided an update on the expansion of its intellectual property estate.

BioLife Solutions Expands Intellectual Property Estate

Only 60 Companies Selected – Based on 2,000 Respondents BOTHELL, Wash. , Nov. 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced that it has been selected for inclusion in the BioSpace Best Places to Work in Biopharma 2023 Report.

BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Mike Rice - Chairman & Chief Executive Officer Rod de Greef - President & Chief Operating Officer Conference Call Participants Paul Knight - KeyBanc Thomas Flaten - Lake Street Jacob Johnson - Stephens Stephanie Iannetta - Cowen and Company Yuan Zhi - B. Riley Securities Suraj Kalia - Oppenheimer Operator Good afternoon, ladies and gentlemen and thank you for standing by.

BioLife Solutions, Inc. (BLFS) Q3 2022 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates

Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow from operations of $1.5 million and adjusted EBITDA of $1.4 million Tightens 2022 revenue guidance range reflecting year-over-year growth of 34% to 38% and organic growth of 37% to 40% Conference call begins at 4:30 p.m. Eastern time today  BOTHELL, Wash.

BioLife Solutions Reports Third Quarter 2022 Financial Results

BOTHELL, Wash. , Nov. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2022 financial results will be released after market close on Wednesday, November 9 th.

BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022

BioLife recently formed a strategic partnership with CSafe to expand its service repertoire for its customers. The latest quarter reported extremely strong growth across all operations.

BioLife: What The Future Holds

CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash. , Oct. 11, 2022 /PRNewswire/ -- CSafe, one of the largest active and passive temperature-controlled shipping solutions providers for pharmaceuticals, and BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy ("CGT") and broader biopharma markets, announced today a new partnership to provide a combined global service network to support CGT products, with a focus on enhanced reliability, security and quality.

CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market

Roderick de Greef retirement planned for January 2023 with appointment to  BioLife Board of Directors Geraint Phillips to assume responsibilities in January 2023 as newly promoted Senior Vice President, Global Operations BOTHELL, Wash. , Oct. 3, 2022 /PRNewswire/ -- BioLife Solutions, Inc.  (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy ("CGT") and broader biopharma markets, today announced changes to its Board of Directors and executive management team, all to be effective as of January 3, 2023.

BioLife Solutions Announces COO to Retire and Join Board of Directors

Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash. , Aug. 25, 2022 /PRNewswire/ --  BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L.

BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Mike Rice - Chairman and Chief Executive Officer Rod de Greef - President and Chief Operating Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Hannah Hefley - Stephens Max Masucci - Cowen and Company Suraj Kalia - Oppenheimer Operator Good day. My name is Chantel, and I'll be your conference operator today.

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q2 2022 Results - Earnings Call Transcript

Record revenue of $40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46% Updating 2022 revenue guidance to $160 million to $166 million, reflecting year-over-year growth of 34% to 39% and higher organic growth expectations of 37% to 43% Sequential improvement in adjusted gross margin; on track for continued improvement in 2022 Positive adjusted EBITDA in Q2 2022 of $1.5 million BOTHELL, Wash. , Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended June 30, 2022.

BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance

BOTHELL, Wash., Aug. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9 th.

BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022

The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level BOTHELL, Wash. , June 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc.

BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial officer Mike Rice - Chairman and Chief Executive Officer Rod De Greef - President and Chief Operating Officer Conference Call Participants Max Masucci - Cowen and Company Jacob Johnson - Stephens Inc. Thomas Flaten - Lake Street Capital Markets Suraj Kalia - Oppenheimer Operator Welcome to the BioLife Solutions First Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2022 Results - Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates

Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39% Sequential Improvement in Gross Margin and Adjusted EBITDA; on track for Continued Improvement in 2022, including positive adjusted EBITDA for the full year Senior Management and Board to accept shares in lieu of a portion of cash compensation to signal confidence in the business BOTHELL, Wash. , May 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2022.

BioLife Solutions Reports First Quarter 2022 Financial Results

BOTHELL, Wash. , May 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that it has executed a co-marketing agreement with Coriell Institute of Medical Research.

BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services

News for BioLife Solutions Stock (BLFS)